Tag Archives: PostCOVID

Post-COVID condition varies by variant and vaccination status – News-Medical.Net

  1. Post-COVID condition varies by variant and vaccination status News-Medical.Net
  2. Profiling post-COVID-19 condition across different variants of SARS-CoV-2: a prospective longitudinal study in unvaccinated wild-type, unvaccinated alpha-variant, and vaccinated delta-variant populations The Lancet
  3. Virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two Omicron subvariants Nature.com
  4. A novel role for macrophage-activation signaling in orchestrating the recruitment process in response to the SARS-CoV-2 spike protein News-Medical.Net
  5. COVID’s latest twist: New XBB variant gains strength through recombination, outsmarting immunity and amplifying fusogenicity News-Medical.Net
  6. View Full Coverage on Google News

Read original article here

Free spike proteins in the blood appear to play a role in myocarditis post-COVID mRNA vaccine

Following the large-scale rollout of the messenger ribonucleic acid (mRNA) vaccines developed to prevent infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and symptomatic coronavirus disease 2019 (COVID-19), several cases of myocarditis were reported, mostly among healthy young people.

A recent study published in the journal Circulation examines the immunological picture in this scenario, looking for clues to the etiology of this rare and potentially serious complication.

Study: Circulating Spike Protein Detected in Post–COVID-19 mRNA Vaccine Myocarditis. Image Credit: Design_Cells / Shutterstock

Introduction

The development of myocarditis following mRNA vaccination is rare, occurring in <2 per 100,000 individuals. It remains an unpredictable mysterious occurrence. Some have suggested that it is linked to the overproduction of antibodies or abnormal immune responses.

Autoantibody production due to polyclonal B cell activation and proliferation has also been suggested, as has immune complex formation and inflammation. Finally, some think that cardiac antigens closely resembling the spike protein are targeted by autoantibodies formed as a result of molecular mimicry.

The immune response to these vaccines in these patients needs to be better understood in order to determine why and how it happens. It is imperative to study the role of male hormones since young male patients are most often affected.

The researchers in this study looked at blood samples from 16 myocarditis patients, confirmed to have high levels of serum cardiac troponin T. All developed myocarditis after receiving the COVID-19 vaccine, typically within a week of the second dose. However, a few became sick after the first dose or booster dose. Over 80% were male.

They were studied by antibody profiling, including antibodies to the virus, autoantibodies or antibodies to the virome, and the analysis of T cells specifically directed against the virus. In addition, cytokine and antigen profiles were determined. These measurements were compared with those of 45 vaccinated controls, who were of similar age and health.

What did the study show?

All subjects and controls showed a rise in anti-spike antibodies and antibodies to the receptor binding domain (RBD), of all immunoglobulin (Ig) subclasses, IgA, IgM, and IgG. Functional differences were not perceived either, with Fc effector functions being similar in both categories. In short, all vaccinated individuals showed evidence of a protective immune response against the virus.

We found no indication that a specific antibody response is associated with myocarditis.”

Additionally, these patients did not show evidence of increased autoantibody production or antibody production against other respiratory pathogens that differed in magnitude or range from the controls.

T cells of all relevant subtypes, including naïve, memory, and effector memory T cells, showed similar distributions in both groups. T cells also showed similar proportions of spike-specific memory CD4 T cells and activated CD4 and CD8 T cells. The only exceptions were the observation of small elevations in effector memory cells and PD-1-expressing bulk CD4 T cells in the myocarditis group.

The findings indicated that antibody and T-cell responses could not distinguish between post-vaccine myocarditis subjects and vaccinated controls. The only significant difference was a slight elevation in cytokine production in the former.

The exciting difference was the high level of circulating full-length spike protein in the plasma of myocarditis patients, at a mean of ~34 pg/mL. Furthermore, the protein was not bound to antibodies and remained detectable for up to three weeks from the vaccination date. In contrast, controls did not have free spike protein in their blood.

This difference could not be attributed to poor neutralizing capacity in the myocarditis group, which showed comparable neutralization relative to the control group.

Concordantly, myocarditis patients had cytokine release patterns resembling those found in multisystem inflammatory syndrome in children (MIS-C). This might indicate that the innate immune response was overactive, leading to elevations in interleukin (IL)-8, IL-10, IL-4, IL-6, tumor necrosis factor (TNF)-α, and interferon (INF)-γ relative to healthy controls. IL-8 was most closely associated with raised cardiac troponin T and antigen levels.

Alongside, leukocytes, especially neutrophils, were at higher mean levels in this group than controls, though still within normal range.

What are the implications?

The study shows that the immunological response elicited by the mRNA vaccine was very similar in those who developed post-vaccination myocarditis and others. In other words, myocarditis could not be associated with abnormal autoantibodies, viral infections other than SARS-CoV-2, or excessive production of antibodies elicited by the mRNA vaccine.

In vaccinated patients, infection with the virus was not likely to be a cause or contributing factor for myocarditis since anti-Nucleoprotein IgG was not found in these patients.

In contrast to controls, the finding of high levels of unbound full-length spike protein in myocarditis patients may point to the mechanism by which this condition arises. Similarly, MIS-C patients had circulating SARS-CoV-2 antigens.

The spike protein appears to evade immune antibodies found at normal levels in these patients, with adequate functional and neutralization capacity. The spike may damage the cardiac pericytes or endothelium, perhaps by reducing the expression of the angiotensin-converting enzyme 2 (ACE2), reducing nitric oxide production in the endothelium, or activating inflammation via integrins, causing the endothelium to become abnormally permeable.

Thus, the spike antigen itself, which evades antibody recognition rather than invoking immune hyperactivation, may contribute to myocarditis in these individuals.”

This finding does not amount to evidence against the benefit of vaccination with these vaccines, which effectively protect against severe COVID-19 outcomes. Therefore, current vaccine recommendations are unlikely to be altered due to these results.

Understanding the immunopathological mechanisms associated with postvaccine myocarditis will help improve safety and guide the development of future coronavirus disease 2019 (COVID-19) vaccines. These findings also suggest that administration of anti-spike antibodies, if spike antigenemia is detected, could potentially prevent or reverse postvaccine myocarditis.”

Read original article here

Free spike proteins in the blood appear to play a role in myocarditis post-COVID mRNA vaccine

Following the large-scale rollout of the messenger ribonucleic acid (mRNA) vaccines developed to prevent infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and symptomatic coronavirus disease 2019 (COVID-19), several cases of myocarditis were reported, mostly among healthy young people.

A recent study published in the journal Circulation examines the immunological picture in this scenario, looking for clues to the etiology of this rare and potentially serious complication.

Study: Circulating Spike Protein Detected in Post–COVID-19 mRNA Vaccine Myocarditis. Image Credit: Design_Cells / Shutterstock

Introduction

The development of myocarditis following mRNA vaccination is rare, occurring in <2 per 100,000 individuals. It remains an unpredictable mysterious occurrence. Some have suggested that it is linked to the overproduction of antibodies or abnormal immune responses.

Autoantibody production due to polyclonal B cell activation and proliferation has also been suggested, as has immune complex formation and inflammation. Finally, some think that cardiac antigens closely resembling the spike protein are targeted by autoantibodies formed as a result of molecular mimicry.

The immune response to these vaccines in these patients needs to be better understood in order to determine why and how it happens. It is imperative to study the role of male hormones since young male patients are most often affected.

The researchers in this study looked at blood samples from 16 myocarditis patients, confirmed to have high levels of serum cardiac troponin T. All developed myocarditis after receiving the COVID-19 vaccine, typically within a week of the second dose. However, a few became sick after the first dose or booster dose. Over 80% were male.

They were studied by antibody profiling, including antibodies to the virus, autoantibodies or antibodies to the virome, and the analysis of T cells specifically directed against the virus. In addition, cytokine and antigen profiles were determined. These measurements were compared with those of 45 vaccinated controls, who were of similar age and health.

What did the study show?

All subjects and controls showed a rise in anti-spike antibodies and antibodies to the receptor binding domain (RBD), of all immunoglobulin (Ig) subclasses, IgA, IgM, and IgG. Functional differences were not perceived either, with Fc effector functions being similar in both categories. In short, all vaccinated individuals showed evidence of a protective immune response against the virus.

We found no indication that a specific antibody response is associated with myocarditis.”

Additionally, these patients did not show evidence of increased autoantibody production or antibody production against other respiratory pathogens that differed in magnitude or range from the controls.

T cells of all relevant subtypes, including naïve, memory, and effector memory T cells, showed similar distributions in both groups. T cells also showed similar proportions of spike-specific memory CD4 T cells and activated CD4 and CD8 T cells. The only exceptions were the observation of small elevations in effector memory cells and PD-1-expressing bulk CD4 T cells in the myocarditis group.

The findings indicated that antibody and T-cell responses could not distinguish between post-vaccine myocarditis subjects and vaccinated controls. The only significant difference was a slight elevation in cytokine production in the former.

The exciting difference was the high level of circulating full-length spike protein in the plasma of myocarditis patients, at a mean of ~34 pg/mL. Furthermore, the protein was not bound to antibodies and remained detectable for up to three weeks from the vaccination date. In contrast, controls did not have free spike protein in their blood.

This difference could not be attributed to poor neutralizing capacity in the myocarditis group, which showed comparable neutralization relative to the control group.

Concordantly, myocarditis patients had cytokine release patterns resembling those found in multisystem inflammatory syndrome in children (MIS-C). This might indicate that the innate immune response was overactive, leading to elevations in interleukin (IL)-8, IL-10, IL-4, IL-6, tumor necrosis factor (TNF)-α, and interferon (INF)-γ relative to healthy controls. IL-8 was most closely associated with raised cardiac troponin T and antigen levels.

Alongside, leukocytes, especially neutrophils, were at higher mean levels in this group than controls, though still within normal range.

What are the implications?

The study shows that the immunological response elicited by the mRNA vaccine was very similar in those who developed post-vaccination myocarditis and others. In other words, myocarditis could not be associated with abnormal autoantibodies, viral infections other than SARS-CoV-2, or excessive production of antibodies elicited by the mRNA vaccine.

In vaccinated patients, infection with the virus was not likely to be a cause or contributing factor for myocarditis since anti-Nucleoprotein IgG was not found in these patients.

In contrast to controls, the finding of high levels of unbound full-length spike protein in myocarditis patients may point to the mechanism by which this condition arises. Similarly, MIS-C patients had circulating SARS-CoV-2 antigens.

The spike protein appears to evade immune antibodies found at normal levels in these patients, with adequate functional and neutralization capacity. The spike may damage the cardiac pericytes or endothelium, perhaps by reducing the expression of the angiotensin-converting enzyme 2 (ACE2), reducing nitric oxide production in the endothelium, or activating inflammation via integrins, causing the endothelium to become abnormally permeable.

Thus, the spike antigen itself, which evades antibody recognition rather than invoking immune hyperactivation, may contribute to myocarditis in these individuals.”

This finding does not amount to evidence against the benefit of vaccination with these vaccines, which effectively protect against severe COVID-19 outcomes. Therefore, current vaccine recommendations are unlikely to be altered due to these results.

Understanding the immunopathological mechanisms associated with postvaccine myocarditis will help improve safety and guide the development of future coronavirus disease 2019 (COVID-19) vaccines. These findings also suggest that administration of anti-spike antibodies, if spike antigenemia is detected, could potentially prevent or reverse postvaccine myocarditis.”

Read original article here

Significant Post-COVID Brain Abnormalities Revealed by Special MRI

Investigators have uncovered brain changes in patients up to six months after they recovered from COVID-19.

Scientists uncovered brain changes in patients up to six months after they recovered from

As more people become infected and recover from COVID-19, research has begun to emerge, focusing on the lasting consequences of the disease. These are known as post-COVID conditions, which are also known by a myriad of names including long COVID, long-haul COVID, post-acute COVID-19, post-acute sequelae of SARS CoV-2 infection (PASC), long-term effects of COVID, and chronic COVID.

For this study, researchers used susceptibility-weighted imaging to analyze the effects that COVID-19 has on the brain. Magnetic susceptibility denotes how much certain materials, such as blood, iron, and calcium, will become magnetized in an applied magnetic field. This ability aids in the detection and monitoring of a host of neurologic conditions including microbleeds, vascular malformations, brain tumors, and stroke.

Group analysis on susceptibility-weighted imaging exhibiting higher susceptibility-weighted imaging values in the COVID group when compared to healthy controls. Three significant clusters were found primarily in the white matter regions of the pre-frontal cortex and in the brainstem. The clusters (a) and (b) are observed bilaterally in the cerebral white matter near the orbitofrontal gyrus, whereas (c) lies in the midbrain region. Credit: RSNA and Sapna S. Mishra

“Group-level studies have not previously focused on COVID-19 changes in magnetic susceptibility of the brain despite several case reports signaling such abnormalities,” said study co-author Sapna S. Mishra, a Ph.D. candidate at the Indian Institute of Technology in Delhi. “Our study highlights this new aspect of the neurological effects of COVID-19 and reports significant abnormalities in COVID survivors.”

The researchers analyzed the susceptibility-weighted imaging data of 46 COVID-recovered patients and 30 healthy controls. Imaging was done within six months of recovery. Among patients with long COVID, the most commonly reported symptoms were fatigue, trouble sleeping, lack of attention, and memory issues.

“Changes in susceptibility values of brain regions may be indicative of local compositional changes,” Mishra said. “Susceptibilities may reflect the presence of abnormal quantities of paramagnetic compounds, whereas lower susceptibility could be caused by abnormalities like calcification or lack of paramagnetic molecules containing iron.”

MRI results showed that patients who recovered from COVID-19 had significantly higher susceptibility values in the frontal lobe and brain stem compared to healthy controls. The clusters obtained in the frontal lobe primarily show differences in the white matter.

“These brain regions are linked with fatigue, insomnia, anxiety, depression, headaches, and cognitive problems,” Mishra said.

Portions of the left orbital-inferior frontal gyrus (a key region for language comprehension and production) and right orbital-inferior frontal gyrus (associated with various cognitive functions including attention, motor inhibition, and imagery, as well as social cognitive processes) and the adjacent white matter areas made up the frontal lobe clusters.

The researchers also found a significant difference in the right ventral diencephalon region of the brain stem. This region is associated with many crucial bodily functions, including coordinating with the endocrine system to release hormones, relaying sensory and motor signals to the cerebral cortex and regulating circadian rhythms (the sleep-wake cycle).

“This study points to serious long-term complications that may be caused by the coronavirus, even months after recovery from the infection,” Mishra said. “The present findings are from the small temporal window. However, the longitudinal time points across a couple of years will elucidate if there exists any permanent change.”

The researchers are conducting a longitudinal study on the same patient cohort to determine whether these brain abnormalities persist over a longer time frame.

Co-authors are Rakibul Hafiz, Ph.D., Tapan Gandhi, Ph.D., Vidur Mahajan, M.B.B.S., Alok Prasad, M.D., and Bharat Biswal, Ph.D.

Meeting: 108th Scientific Assembly and Annual Meeting of the Radiological Society of North America



Read original article here

MRI Reveals Significant Brain Abnormalities Post-COVID

Summary: Neuroimaging study reveals significant brain changes in areas associated with language comprehension, cognition, and circadian rhythm control six months after COVID-19 infection.

Source: RSNA

Using a special type of MRI, researchers have uncovered brain changes in patients up to six months after they recovered from COVID-19, according to a study being presented next week at the annual meeting of the Radiological Society of North America (RSNA).

About one in five adults will develop long-term effects from COVID-19, according to the U.S. Centers for Disease Control and Prevention. Neurological symptoms associated with long COVID include difficulty thinking or concentrating, headache, sleep problems, lightheadedness, pins-and-needles sensation, change in smell or taste, and depression or anxiety. However, studies have found that COVID-19 may be associated with changes to the heart, lungs or other organs even in asymptomatic patients.

As more people become infected and recover from COVID-19, research has begun to emerge, focusing on the lasting consequences of the disease.

For this study, researchers used susceptibility-weighted imaging to analyze the effects that COVID-19 has on the brain. Magnetic susceptibility denotes how much certain materials, such as blood, iron and calcium, will become magnetized in an applied magnetic field. This ability aids in the detection and monitoring of a host of neurologic conditions including microbleeds, vascular malformations, brain tumors and stroke.  

“Group-level studies have not previously focused on COVID-19 changes in magnetic susceptibility of the brain despite several case reports signaling such abnormalities,” said study co-author Sapna S. Mishra, a Ph.D. candidate at the Indian Institute of Technology in Delhi. “Our study highlights this new aspect of the neurological effects of COVID-19 and reports significant abnormalities in COVID survivors.”

The researchers analyzed the susceptibility-weighted imaging data of 46 COVID-recovered patients and 30 healthy controls. Imaging was done within six months of recovery. Among patients with long COVID, the most commonly reported symptoms were fatigue, trouble sleeping, lack of attention and memory issues.

“Changes in susceptibility values of brain regions may be indicative of local compositional changes,” Mishra said. “Susceptibilities may reflect the presence of abnormal quantities of paramagnetic compounds, whereas lower susceptibility could be caused by abnormalities like calcification or lack of paramagnetic molecules containing iron.”

MRI results showed that patients who recovered from COVID-19 had significantly higher susceptibility values in the frontal lobe and brain stem compared to healthy controls. The clusters obtained in the frontal lobe primarily show differences in the white matter.

“These brain regions are linked with fatigue, insomnia, anxiety, depression, headaches and cognitive problems,” Mishra said.

Group analysis on susceptibility-weighted imaging exhibiting higher susceptibility-weighted imaging values in the COVID group when compared to healthy controls. Three significant clusters were found primarily in the white matter regions of the pre-frontal cortex and in the brainstem. Credit: RSNA and Sapna S. Mishra

Portions of the left orbital-inferior frontal gyrus (a key region for language comprehension and production) and right orbital-inferior frontal gyrus (associated with various cognitive functions including attention, motor inhibition and imagery, as well as social cognitive processes) and the adjacent white matter areas made up the frontal lobe clusters.

See also

The researchers also found a significant difference in the right ventral diencephalon region of the brain stem. This region is associated with many crucial bodily functions, including coordinating with the endocrine system to release hormones, relaying sensory and motor signals to the cerebral cortex and regulating circadian rhythms (the sleep-wake cycle).

“This study points to serious long-term complications that may be caused by the coronavirus, even months after recovery from the infection,” Mishra said. “The present findings are from the small temporal window. However, the longitudinal time points across a couple of years will elucidate if there exists any permanent change.”

The researchers are conducting a longitudinal study on the same patient cohort to determine whether these brain abnormalities persist over a longer time frame.

Co-authors are Rakibul Hafiz, Ph.D., Tapan Gandhi, Ph.D., Vidur Mahajan, M.B.B.S., Alok Prasad, M.D., and Bharat Biswal, Ph.D.

About this neurology and COVID-19 research news

Author: Linda Brooks
Source: RSNA
Contact: Linda Brooks – RSNA
Image: The image is credited to RSNA and Sapna S. Mishra

Original Research: The findings will be presented at the 108th Scientific Assembly and Annual Meeting of the Radiological Society of North America

Read original article here

Post-COVID Fatigue, Exercise Intolerance Signal ME/CFS – Medscape

  1. Post-COVID Fatigue, Exercise Intolerance Signal ME/CFS Medscape
  2. Kern County covid-19 numbers, plus concerns about the link between long covid and suicide KERO 23 ABC News Bakersfield
  3. Post COVID-19 mental health symptoms and quality of life among COVID-19 frontline clinicians: a comparative study using propensity score matching approach | Translational Psychiatry Nature.com
  4. Prior Psychological Distress Tied to ‘Long COVID’ Conditions Medscape
  5. Long COVID’s link to suicide: scientists warn of hidden crisis CTV News
  6. View Full Coverage on Google News

Read original article here

Luxury stores still limiting crowds post-COVID — and won’t admit why

COVID-19 is waning, but shopping for a Louis Vuitton bag, a Chanel suit or a pair of Gucci loafers increasingly means standing in line outside a boutique — and luxury brands have been conspicuously tight-lipped on why.

Most elite labels leaned into “appointment shopping” during the height of the pandemic, citing the need for social distancing. But as the threat from the virus recedes, some including Cartier and Harry Winston continue to impose the new policy.

They also have failed to convince shoppers and experts alike of their reasoning — if they bother to explain themselves at all. Major brands including Louis Vuitton, Chanel and Cartier didn’t respond to calls and emails from The Post about their persistent use of stanchions in front of store entrances, where queued-up shoppers are quizzed by “greeters” about prospective purchases before entering.

Chanel said it will open “private” stores for its top customers next year.
Bloomberg via Getty Images

“We recommend booking an appointment prior to your boutique visit, as walk-ins may experience extended wait times,” Cartier’s website advises, without elaborating.

According to experts, roped-off customers can mostly thank a relentless epidemic of smash-and-grab robberies rather than social distancing for ramped-up crowd controls nationwide, including in New York, Chicago, Miami, San Francisco and Seattle. Theft got so bad last year that Beverly Hills hired two private security firms to patrol Rodeo Drive.

Meanwhile, at the Westchester Mall in White Plains, NY, where robbers ransacked a Louis Vuitton store in February, the boutique’s doors were closed, with stanchions inviting shoppers to queue up outside.

Some luxury boutiques question customers before they enter the store, asking what they are looking for.
Jeffrey Greenberg/UCG/Universal

A pair of greeters wearing headsets — flanked by a pair of beefy mall security guards — asked customers whether they were there to pick up an order or to shop. Shoppers were let in only when an associate was ready to accompany them inside.

“They don’t want customers looking around the store without a store employee with them,” a sales associate told The Post. 

Beverly Hills hired private security companies to patrol after smash-and-grab crime surged this year.
MEGA

Luxury brands have managed to obscure the embarrassment of the situation partly because making it difficult to enter their stores “creates an aura of exclusivity,” says Steve Dennis, a Dallas-based retail consultant.

“Most of these stores aren’t crowded anyway,” and the lines are getting longer in states like Texas, “which didn’t particularly take COVID seriously,” said Dennis, author of “Remarkable Retail: How to Win & Keep Customers in the Age of Disruption.”

“The new nightclub, in its own weird way, is getting into a Dolce & Gabbana store on a Saturday,” adds luxury retail consultant Melanie Holland.

Gucci is among the luxury brands where customers are asked to wait in line before entering stores.
Bloomberg via Getty Images
luxury boutiques across the country, including this Miami Gucci store, limit how many customers can enter at one time.
Jeffrey Greenberg/UCG/Universal

Last week, a Chanel executive provoked chatter when he disclosed in an interview that the company plans to open “private” boutiques in Asia next year for top clients. Chanel is hiring 3,500 new employees for the initiative, which experts say could be adopted in the US.

“Our biggest preoccupation is to protect our customers and in particular our pre-existing customers,” Chanel’s chief financial officer Philippe Blondiaux told Business of Fashion. “We’re going to invest in very protected boutiques to service clients in a very exclusive way.”

In response, fashion blog Highsnobiety questioned “What, exactly, do Blondiaux and Chanel want to ‘protect’ its customers from?”

Holland speculated that Chanel may be looking to keep its wealthy clients from becoming targets for thieves after they leave stores. But big spenders also aren’t typically walking in off the street, she adds.

“People who want to spend $25,000 for a small dress don’t want to stand in line,” Holland said. “Those customers are probably making an appointment with their personal shopper — they know that line isn’t meant for them.”

Some luxury stores are still requiring customers to make an appointment to shop.
Bloomberg via Getty Images

As previously reported by The Post, Madison Avenue boutiques on the Upper East Side in Manhattan including Chanel, Prada and Carolina Herrera are dimming their lights, locking their doors, and opening by appointment only in a bid to deter a wave of brazen daytime shoplifters that have terrorized the glitzy thoroughfare this year.

In February, a team of seven thieves strolled out of The Real Real on Madison at 71st Street with nearly $500,000 worth of handbags and jewelry.

In the wake of such heists, there is simply a “new lack of trust” on the part of retailers “about who is walking through their doors,” said Susan Scafidi, founder and director of the Fashion Law Institute at Fordham Law School.

In practice, most luxury brands assign a sales associate to each customer or group. The days of walking into an exclusive boutique and “browsing” without an associate shadowing you are largely over, said one sales rep.

Meanwhile, staffers at upscale boutiques including Chanel, Gucci and Burberry are being armed with talking points for inquisitive customers, some of which sound plausible.

“We are still dealing with shipping delays from Paris and you don’t want everyone to come in and to notice that the store doesn’t have the latest styles,” a sales associate at a boutique operated by a major luxury label told The Post, speaking on the condition of anonymity.

“You want to be able to tell them one-on-one that the pieces are on the way,” the associate added.

Read original article here

“Long COVID” or “post-COVID” symptoms affect 1 in 4 seniors who survived infection, study finds

As many as one in four seniors and one in five adults under 65 experienced “long COVID” or “post-COVID” symptoms after surviving a coronavirus infection, a new study from the Centers for Disease Control and Prevention reported Tuesday. 

The study — published in the CDC’s Morbidity and Mortality Weekly Report — is the latest to try and quantify how many of the millions of Americans who have now tested positive for the virus are facing long-term issues caused by their infection.

By comparing electronic health records in a large national database of patients, the study’s authors found 38.2% of COVID-19 survivors “experienced at least one incident condition” — a list that includes heart, lung, kidney and gastrointestinal problems, pain, fatigue, loss of smell or taste, mental health issues, and more —  in the months after their infection. By contrast, just 16% of other people were diagnosed with such conditions.

“As the cumulative number of persons ever having been infected with SARS-CoV-2 increases, the number of survivors suffering post-COVID conditions is also likely to increase,” the study’s authors wrote. 

The study only looked at data from March 2020 to November 2021, before the massive Omicron variant surge over the winter. Based on surveys of antibodies, the CDC estimates that the share of Americans who have survived the virus rose to nearly 60% over the winter, up from a third in December.

Among the 26 conditions examined by the study, the most common symptoms were “respiratory symptoms and musculoskeletal pain” in both seniors and other adults. 

Among seniors aged 65 years and older, the researchers warned they were at “increased risk for neurological conditions” and other mental health issues ranging from mood disorders to substance abuse.

Another study also published this week, from scientists at Northwestern University, reported that many so-called “long haulers” were facing conditions like brain fog and numbness for more than a year after their initial infection. 


Doctor urges people not to give up on pandemic precautions because of long COVID risk

06:55

The CDC study’s authors also note there are some factors that might complicate their estimates. 

For example, doctors may have been “more likely to document possible post-COVID conditions” among people who have survived the virus, leading to an overestimate of the risk of these symptoms. 

On the other hand, the study’s comparison to others without a prior infection was drawn from other patients who were “seeking care.” That could lead to an underestimate of the true risk elevated by an infection, the study’s authors said, given these others might actually be “sicker” than a true control group.

Previous studies have reached varying estimates of the share of survivors who face long COVID symptoms. Some of that may be the result of the wide range of ways scientists have defined post-COVID in their studies, looking at different time intervals since infection or different symptoms.

“You see numbers out there of like 30, 50 percent. I think that’s clearly not quite right in terms of thinking about how many people are really disabled by this in a significant way,” Dr. Ashish Jha, the White House’s top COVID-19 official, told the “In the Bubble” podcast earlier this month. 

“But that said, what that means, unfortunately, is other people minimize long COVID,” Jha added.

The latest report is among several ongoing studies the CDC has backed with the aim of understanding the impact of post-COVID symptoms. 

The CDC revamped its guidance on post-COVID earlier this month, adding conditions like “depression or anxiety” to the list of commonly reported symptoms. The agency also laid out a list of reasons some people might be at higher risk after surviving COVID-19, like those who have faced a more severe illness or who were unvaccinated. 

However, the guidance notes that more research – including both from the CDC and elsewhere at the National Institutes of Health – still needs to be done into how to treat these post-COVID patients. 

Advocates said recently that they are in talks with the Biden administration over long COVID plans to be released in August. The NIH has said it plans to launch studies this year into trialing potential drugs to treat post-COVID conditions.

“I think we need to start trying out new therapies. I am interested in questions like, does getting Paxlovid reduce your likelihood of long COVID. Because if you have a much shorter duration of viremia is that going to make a difference?” said Jha.



Read original article here

Post-COVID Psychosis Is Real. Here’s What To Know About It.

From the very beginning of the pandemic, it has been clear that COVID can have as profound an impact on mental health as it does on physical well-being.

Rates of depression and anxiety have spiked around the globe, even among those who’ve never been sick. For those who have been infected, the risk is higher. People who’ve had COVID-19 and have recovered are more likely to be diagnosed with depression or anxiety in the year after their illness, and they’re more susceptible to sleep problems and substance abuse, too.

For a small subset of those patients, the connection can be especially sudden and severe. For more than two years, doctors around the world have published case reports describing COVID-related psychosis, telling stories of previously healthy individuals who suddenly develop symptoms like hallucinations or violent delusions.

And the causes are still not clear.

The COVID and mental health connection

In so many ways, the pandemic has whipped up a perfect storm for mental health issues. There’s the stress and isolation of pandemic living, and there are millions of people dealing with the fallout of an infection and long COVID. Loss, fear, uncertainty and physical pain have upended many people’s lives.

But researchers increasingly believe there is a biological underpinning to the COVID-related mental health crisis as well. The virus puts people at greater risk of health problems like inflammation and blood clots that can take a toll on the brain. There’s also some evidence suggesting the virus may directly enter the brain itself — though that research is still very preliminary.

Regardless, it is clear that the relationship between COVID and mental health issues is complex. Mental health experts have known for some time that people with schizophrenia or mood disorders, like depression, may be at greater risk for getting really sick if they are infected with COVID. The why, again, isn’t known.

It is possible, for example, that people with schizophrenia have underlying immune system disturbances that increase their risk of severe illness if they are infected with COVID-19. But researchers haven’t ruled out the very real possibility that it could be something else. Social determinants of health, like economic stability or access to health care, could also be factors. Those kinds of stressors can put people at greater risk of certain mental health issues, and can also increase the likelihood of severe illness if they get COVID.

“This COVID-19 psychosis is mysterious … most cases seem to occur out the of the blue and we don’t know why.”

– Dr. Cristopher Bartley, immunopsychiatrist

The mysteries of sudden-onset psychosis

There are no solid estimates on how many people around the world have developed sudden-onset psychosis after a COVID infection, but the available data shows that it is rare. Still, mental health experts say it is an important issue to track because there’s still so much they do not understand about it.

Most case reports are puzzling, in that they’ve cropped up in individuals with no previous mental health issues, and the symptoms are severe. Case studies have described patients becoming physically and verbally aggressive, seemingly out of the blue. Some came to believe their health care providers are out to kill them. Others began hearing voices. With psychotic disorders — a category that includes schizophrenia — people become detached from reality, and can experience hallucinations and delusions.

“There’s still a lot we don’t know about the relationship between COVID-19 and psychosis. What we do know is that there are many causes of psychosis, including infection,” said Dr. Cristopher Bartley, an immunopsychiatrist at the University of California San Francisco who worked on a 2021 study looking at three teenagers with COVID who developed severe and sudden psychiatric symptoms.

Bartley explained that other viruses, such as herpes simplex, can cross into the central nervous system and cause severe complications like autoimmune encephalitis — basically, inflammation of the brain that can cause psychosis. But he cautioned that the evidence at this point that SARS-CoV-2 (the virus that causes COVID) can directly infect brain cells is “weak.”

One hypothesis that Bartley said is gaining traction is the idea of autoimmune psychosis. The SARS-CoV-2 virus basically wreaks havoc on the immune system to the point where the body starts attacking itself, including the central nervous system. But that theory, at this point, is by no means a perfect one, Bartley emphasized. Doctors aren’t finding the kinds of biomarkers of autoimmune psychosis that would support the idea.

“This COVID-19 psychosis is mysterious,” Bartley said. “Most cases seem to occur out the of the blue and we don’t know why.”

A call for more research

Mental health experts stress that researchers need to take the phenomenon seriously, if for no other reason than the virus is not going anywhere.

Psychosis itself remains under-treated, with many people waiting years before seeking help. So it is possible that in some cases the timing of people’s psychosis is coincidental, Bartley said. About 3.5% of people experience a psychotic episode at some point in their lives, making it more common than many realize.

It is too soon at this point to tell what the long-term outlook is for people who develop severe symptoms of psychosis after COVID infection. There are some reasons to be hopeful, however.

“Fortunately, there are a number of cases where COVID-19 psychosis seems to resolve without intervention,” Bartley said. “We don’t have indications yet that SARS-CoV-2 leads to schizophrenia, which is a stable lifelong form of psychosis. This is reassuring.”

Still, much about why some otherwise healthy people develop this kind of severe response remains a mystery — which makes treatment and prevention difficult.

Psychosis can be treated through a combination of therapy and antipsychotic medications. Sometimes it’s necessary for people to receive care in a hospital or rehab setting. In the case of chronic conditions like schizophrenia, there are ways to manage it throughout a person’s life.

But in order to help, doctors and researchers must understand the root causes. And with post-COVID psychosis, there are more questions than answers at this point.

“There’s still a lot,” Hartley said, “that we don’t know.”

Experts are still learning about COVID-19. The information in this story is what was known or available as of publication, but guidance can change as scientists discover more about the virus. Please check the Centers for Disease Control and Prevention for the most updated recommendations.

fbq('init', '1621685564716533'); fbq('track', "PageView");

var _fbPartnerID = null; if (_fbPartnerID !== null) { fbq('init', _fbPartnerID + ''); fbq('track', "PageView"); }

(function () { 'use strict'; document.addEventListener('DOMContentLoaded', function () { document.body.addEventListener('click', function(event) { fbq('track', "Click"); }); }); })();

Read original article here

Cramer sees post-Covid staying power for Etsy, Cash App parent Block

Etsy and Block are Covid-era winners that will continue to thrive even after the pandemic, CNBC’s Jim Cramer contended on Friday.

“You need to understand just how special these stocks are,” the “Mad Money” host said. “While they can have some huge swings, once the volatility’s over, I bet they won’t easily give back their gains.”

Etsy shares soared 16% Friday after the e-commerce marketplace provider reported better-than-expected earnings and revenue Thursday. Even with Friday’s big move, the stock is down nearly 50% over the past three months. The steep decline came as Wall Street rotated into more defensive parts of the stock market and as investors questioned the staying power of pandemic success stories.

Shares of Block, formerly known as Square, skyrocketed 26% Friday after beating Wall Street expectations on earnings and revenue for its fourth quarter. The company also released a rosy outlook for the current quarter and full-year based on the growth of its mobile payment service, Cash App.

Like Etsy’s, Block’s stock has been crushed in recent months. It’s still down more than 40% over the past three months, despite Friday’s gains.

Cramer, who previously warned that many companies aren’t ready for a post-pandemic world, said that the payment giant is “firing on all cylinders” and praised Cash App as “brilliant.” 

As for Etsy, Cramer said the e-commerce shopping platform’s growth internationally, evidenced by its recent increase in transaction fees from 5% to 6.5%, signals a path to success even after the pandemic. “Because of Etsy’s unique nature as the No. 1 marketplace for handcrafted goods, I doubt there will be any resistance,” he added.

Cramer also named DoorDash and Airbnb as other Covid-era winners that he believes will continue to succeed post-pandemic.

Sign up now for the CNBC Investing Club to follow Jim Cramer’s every move in the market.

Read original article here